NTLA Q4 2021 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+94.9% YoY

Gross Profit

-$58M-453.6% margin

Operating Income

-$80M-625.6% margin

Net Income

-$81M-632.0% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+78.4%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$58M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$254M

Stockholders' Equity

$1.0B

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$7M	+94.9%
Gross Profit	-$58M	-$32M	-84.3%
Operating Income	-$80M	-$42M	-89.7%
Net Income	-$81M	-$42M	-92.5%